GLP1R and type 1 diabetes mellitus: In a real‐world retrospective cohort study involving 992 individuals with T1D managed with SGLT2i and 1822 patients with T1D treated with GLP‐1 RA, both therapies resulted in significant reductions in HbA1c over a period of five years (reduction of 0.2% and 0.5%, respectively).91